缺血性中风中的遗传多态化和细胞因子水平:与亚型的关联和预后
Gaetano Pacinella1, Anna Maria Ciaccio1, Alessandra Casuccio1
1Internal Medicine and Stroke Care Ward, Policlinico "P. Giaccone", Palermo; PROMISE Department, University of Palermo, Palermo, Italy.
Expert review of clinical immunology
|June 5, 2025
概括
促炎性细胞因子和凝血因子的遗传变异与缺血性中风风险和亚型有关. 高水平的TNF-α,IL-6和IL-1β与特定类型的中风和中风复发有关.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 遗传学 是一个遗传学.
背景情况:
- 遗传多态度会影响中风风险,但个体贡献很小.
- 炎症和凝血途径与缺血性中风的病原发生有关.
研究的目的:
- 评估中风患者中细胞因子和凝固因子基因中单核酸多态度 (SNP) 的频率.
- 为了研究血清细胞因子水平,中风亚型和预后之间的关系.
主要方法:
- 追溯性,横截面性,观察性,分析性,病例控制性研究.
- 在入院时对多态的遗传分析和血清细胞因子水平 (IL-10,TNF-alpha,IL-6,IL-1β) 的测量.
- 对429名缺血性中风患者和195名对照患者的分析.
主要成果:
- 患有CEI亚型的患者的IL-10,TNF-alpha和IL-6水平显著更高.
- 增加的TNF-α,IL-6和IL-1β水平与LAAS和CEI中风亚型有关.
- 较高的TNF-α,IL-1和IL-6水平与复发性中风相关.
- 特定的PTSG2基因多态 (rs6275,rs20417) 在患者和对照组之间显示出不同的分布.
结论:
- 这项研究证实了炎症标志物和缺血性中风之间的关联.
- 这些发现支持了免疫炎症变量和特定遗传多态性在中风风险和进展中的作用.
相关概念视频
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
126
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
126
Pharmacogenetics of Drug Metabolism: Overview
150
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
150
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
228
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
228
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
69
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
Pharmacogenomics: Identification of New Drug Targets
92
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
92


